Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker Repays All Outstanding Debt In Q2, Eyes Ortho/Endoscopic Purchases

This article was originally published in The Gray Sheet

Executive Summary

Stryker is readying for acquisitions in the $100 mil.-$200 mil. range now that the company is "virtually debt-free," CEO John Brown stated in a second-quarter earnings call July 15

You may also be interested in...

Stryker Backs Artificial Disc Developer For Entry Into $1 Bil. Market

A 400-patient, 20-center clinical trial supporting a PMA application for SpineCore's FlexiCore lumbar total artificial disc will conclude enrollment by the first half of 2005, Stryker estimates

Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts